Catalyst
Slingshot members are tracking this event:
Kite Pharma Initiates Phase 1b/2 Combination Study for KTE-C19 and Atezolizumab in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| KITE | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 06, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Kte-c19, Atezolizumab, Dlbcl
